More binding of a brain-imaging tracer is not automatically evidence of more healthy neurons. A methamphetamine PET study unexpectedly found higher VMAT2-related tracer binding during early abstinence, challenging a simple interpretation of this marker.
Boileau and colleagues studied 16 recently withdrawn methamphetamine users and 14 matched healthy controls. Abstinence averaged 19 days, with a range of one to 90 days. PET imaging used the radioligand (+)[11C]dihydrotetrabenazine, which binds the vesicular monoamine transporter VMAT2.
The researchers expected lower binding, based on concerns about dopamine-terminal damage. Instead, binding was higher in the methamphetamine group: approximately 22% in caudate, 12% in putamen and 11% in ventral striatum. Caudate elevation was greatest among those abstinent for one to three days.
One proposed explanation was altered vesicular dopamine storage affecting tracer binding. If binding depends partly on that state, it may not serve as a stable count of dopamine-neuron integrity. The authors cautioned that an increase might mask a toxic effect rather than exclude it.
This explanation was a hypothesis about the observed imaging pattern. The experiment did not directly count living dopamine terminals or establish that greater binding represented compensatory growth, permanent injury, or recovery.
The imaging endpoint was radioligand binding in brain regions, not a methamphetamine concentration in blood or urine. Positive urine findings were not grounds for excluding methamphetamine participants on scan day. Cognitive testing occurred on another day, after more than seven days of abstinence, so the cognitive and imaging measurements should not be treated as perfectly simultaneous.
The small sample and comparisons across different abstinence durations limit causal inference. Differences between participants cannot establish an individual’s time course of brain recovery.
The study is a reminder to understand a biomarker’s biology before treating its direction as good or bad. It does not validate PET as an individual impairment test. A related measurement problem arises in brain spectroscopy research, where a neurochemical signal also requires interpretation distinct from behavior.
Read the primary study (DOI: 10.1523/JNEUROSCI.3008-08.2008).